...
机译:
Department of Hepatogastroenterology and GI Oncology Georges Pompidou European Hospital;
INSERM UMRS-1138 Centre des Cordeliers University of Paris;
Department of Pathology Beaujon HospitalDepartment of Pathology La Pitié-Salpêtrière Hospital Assistance Publique-H?pitaux de Paris;
BRCA1 promotor; DNA methylation; Homologous recombination; Pancreatic adenocarcinoma; PARP inhibitors; RAD51C promotor;
机译:Editorial on: Moving Beyond Anatomic Criteria for Resectability: Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery
机译:ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy Changes Body Composition Influencing Long-term Outcomes
机译:Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy
机译:乳腺癌和卵巢癌高危人群中意大利家庭的BRCA1和RAD51C启动子甲基化分析
机译:Transcription Repressor slug promotes Carcinoma Invasion and predicts Outcome of patients with Lung adenocarcinoma